A new peptide, murikal/SPR4, was found to significantly increase hair growth in mice, and its liposomal topical formulations enhanced hair growth more than commercial products. However, results on human scalp skin were unclear, needing more tests.
60 citations
,
May 2015 in “Archives of dermatological research” PPAR agonists show promise for skin conditions but need more research before being a main treatment.
52 citations
,
May 2011 in “Journal of Neuroendocrinology” PEA boosts allopregnanolone production and reduces oxidative stress in brain cells.
July 2022 in “Journal of Investigative Dermatology” Blocking DPP4 can help activate hair growth and improve hair regeneration.
43 citations
,
January 1999 in “Endocrinology” Cortisol increases a specific protein in bone cells, which may help explain its negative effects on bone.
April 2025 in “Frontiers in Pharmacology” Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
February 2026 in “International Journal of Nanomedicine” The system improved diabetic wound healing in rats.
28 citations
,
November 2009 in “European Journal of Neuroscience” Progesterone and allopregnanolone increase glycine release in rat brain cells.
1 citations
,
June 2022 in “JCRPE” Metreleptin treatment significantly improved metabolic health in a boy with congenital generalized lipodystrophy.
May 2026 in “Journal of Nanobiotechnology” A new peptide delivered through microneedles can effectively promote hair regrowth.
2 citations
,
December 2010 in “Zhonghua neifenmi daixie zazhi” AHST shows promise for treating type 1 diabetes but needs more research before widespread use.
January 2017 in “Open Journal of Endocrine and Metabolic Diseases” The document concludes that managing Dunnigan-Type Familial Partial Lipodystrophy involves treating associated health issues and using medications like metformin and leptin replacement.
March 2026 in “ACS Applied Materials & Interfaces” MCP@G improves diabetic wound healing by reducing stress and promoting tissue repair.
October 2021 in “JAAD Case Reports” Topical glycopyrrolate lotion helped reduce excessive sweating from eating in a diabetic man.
1 citations
,
August 2022 in “JAAD case reports” Pioglitazone use was linked to hair regrowth in a patient with permanent hair loss from cicatricial alopecia.
16 citations
,
November 2018 in “Medicinal Chemistry” The compound GD-23 may reduce anxiety like diazepam by targeting the TSPO receptor.
1 citations
,
October 2005 in “Experimental and Clinical Endocrinology & Diabetes” Allopregnanolone and opioids together reduce stress hormone responses during pregnancy.
128 citations
,
March 1996 in “Journal of Investigative Dermatology” November 2025 in “Scientia Pharmaceutica” Injectable biostimulators can improve skin by boosting collagen and fat cell activity, but more research is needed to confirm their safety and effectiveness.
62 citations
,
November 2022 in “Acta Pharmaceutica Sinica B” The injectable hydrogel effectively speeds up chronic wound healing.
23 citations
,
December 2017 in “Scientific Reports” ARL15 is important for fat cell development and the release of the hormone adiponectin.
1 citations
,
May 1992 in “Pharmacological Research” July 2026 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Improved CRBN ligands make protein degraders more effective and drug-like.
July 2025 in “Journal of Investigative Dermatology” Upadacitinib effectively treats pyoderma gangrenosum.
32 citations
,
January 2007 in “KARGER eBooks” Severe insulin resistance can be managed with medication, lifestyle changes, and treatment for related conditions.
23 citations
,
January 2016 in “Frontiers in immunology” Using low-dose IL-2 to increase regulatory T cells might be a safe way to treat type 1 diabetes without severe side effects.
24 citations
,
April 2008 in “Fertility and sterility” Pioglitazone improved insulin sensitivity and altered cortisol metabolism in PCOS patients.
August 2020 in “Research Square (Research Square)” Enhanced stem cells can reduce fat buildup in eye tissue for Graves' disease.
February 2024 in “Experimental Dermatology” IGFBP-rP1 could be a new treatment for a common type of hair loss.